Imbruvica - Beechwood Capital

Imbruvica ibrutinib APPROVED

Drug Profile

ModalitySmall molecule

RoutePO

Therapy AreaOncology

Launch2013-11-13

US LOE2027-01-01

Peak Sales Est$6000M

Formulations[{"id":"imbruvica-po","doses":"140-560mg","route":"PO","setting":"OUTPATIENT","frequency":"Once dail

Companies

ABBV (CO_DEVELOPER)50%

JNJ (CO_DEVELOPER)50%

Mechanism: BTK inhibitor

Expert: Selective covalent inhibitor of Bruton's tyrosine kinase that disrupts B-cell receptor signaling critical for CLL and MCL survival.

Everyday: Blocks a protein that B-cell cancers need to survive and grow.

Targets: ["BTK"]

Revenue History

Programs (2)

Indication	Stage	Key Study	Regional Status
R/R CLL	APPROVED	RESONATE	[{"stage":"APPROVED","region":"US","approval_date":"2014-07-28"}]
R/R MCL	APPROVED	MCL3001	[{"stage":"APPROVED","region":"US","approval_date":"2013-11-13"}]

Notes

First-in-class BTK inhibitor for CLL, MCL. Co-developed with J&J. Facing competition from next-gen BTK inhibitors. 2025 revenue $2.9B (down 14% YoY).

Data from Supabase · Updated 2026-03-24